AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33991221 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal estriol 0.03 mg plus Lactobacillus acidophilus 100 million viable cell vaginal tablets
Number of subjects: 78
Study 33991221 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 78
Study 32390563 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg/day
Number of subjects: 48
Study 32390563 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 35286921 — intervention group
Group type: EXPERIMENTAL
Intervention: Suspected fetal growth restriction (FGR)
Number of subjects: 1902
Study 32668323 — intervention group
Group type: EXPERIMENTAL
Intervention: LUS-guided treatment
Number of subjects: 126
Study 32668323 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 126
Study 33501671 — intervention group
Group type: EXPERIMENTAL
Intervention: Nusinersen (12‐mg scaled equivalent dose)
Number of subjects: 21
Study 33501671 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 21
Study 33501671 — intervention group
Group type: COMPARATOR
Intervention: Transitioned from sham to nusinersen
Number of subjects: 21
Study 33113900 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervisors' workaholism
Number of subjects: 0
Study 34489756 — intervention group
Group type: EXPERIMENTAL
Intervention: LIFEwithIBD intervention + Treatment As Usual (TAU)
Number of subjects: 61
Study 34489756 — intervention group
Group type: COMPARATOR
Intervention: Treatment As Usual (TAU)
Number of subjects: 61
Study 32266682 — intervention group
Group type: EXPERIMENTAL
Intervention: Canine assisted occupational therapy (n=11)
Number of subjects: 22
Study 32266682 — intervention group
Group type: COMPARATOR
Intervention: Occupational therapy sessions as usual (waitlist control group, n=11)
Number of subjects: 22
Study 35483209 — intervention group
Group type: EXPERIMENTAL
Intervention: ALIMFUS therapy for 10 minutes on alternate days for 90 days
Number of subjects: 186
Study 35483209 — intervention group
Group type: EXPERIMENTAL
Intervention: ALIMFUS therapy
Number of subjects: 186
Study 35483209 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 186
Study 34678762 — intervention group
Group type: EXPERIMENTAL
Intervention: SGLT-2 inhibitors
Number of subjects: 68
Study 34678762 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 35922010 — intervention group
Group type: COMPARATOR
Intervention: Closed Treatment (CT)
Number of subjects: 116
Study 32992206 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive group session focused on stroke education
Number of subjects: 199
Study 32992206 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 199
Study 35381064 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin at optimal dose of 160 mg/m2 during concurrent phase
Number of subjects: 742
Study 35381064 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin at optimal dose of 260 mg/m2 during induction/adjuvant phase
Number of subjects: 742
Study 35381064 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin throughout treatment (no replacement by carboplatin)
Number of subjects: 742
Study 34311679 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 116
Study 34311679 — intervention group
Group type: COMPARATOR
Intervention: Control group (no zinc supplementation)
Number of subjects: 116
Study 32552805 — intervention group
Group type: EXPERIMENTAL
Intervention: Peyton's '4-step Approach' (n=45)
Number of subjects: 102
Study 32552805 — intervention group
Group type: COMPARATOR
Intervention: Halsted's 'See One, Do One' (n=57)
Number of subjects: 102
Study 35105640 — intervention group
Group type: EXPERIMENTAL
Intervention: WeChat applet+step goal setting+gamification
Number of subjects: 108
Study 35105640 — intervention group
Group type: EXPERIMENTAL
Intervention: WeChat applet+step goal setting+gamification+collaboration
Number of subjects: 108
Study 35105640 — intervention group
Group type: COMPARATOR
Intervention: WeChat applet+step goal setting
Number of subjects: 108
Study 32833698 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin powder
Number of subjects: 175
Study 32833698 — intervention group
Group type: COMPARATOR
Intervention: No vancomycin powder
Number of subjects: 175
Study 35641012 — intervention group
Group type: EXPERIMENTAL
Intervention: Behaviour change physiotherapy intervention (6, 30 min weekly group-based exercise sessions preceded by a 30 min cognitive behaviour discussion group)
Number of subjects: 224
Study 35641012 — intervention group
Group type: COMPARATOR
Intervention: Usual care (6, 30 min weekly group-based exercise sessions)
Number of subjects: 224
Study 35641012 — intervention group
Group type: EXPERIMENTAL
Intervention: Behaviour change physiotherapy intervention
Number of subjects: 224
Study 35641012 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 224
Study 33093457 — intervention group
Group type: EXPERIMENTAL
Intervention: IRE plus allogeneic γδ T-cell infusion (Group A)
Number of subjects: 62
Study 33093457 — intervention group
Group type: EXPERIMENTAL
Intervention: IRE plus allogeneic γδ T-cell infusion (multiple courses)
Number of subjects: 62
Study 33093457 — intervention group
Group type: EXPERIMENTAL
Intervention: IRE plus allogeneic γδ T-cell infusion (single course)
Number of subjects: 62
Study 33093457 — intervention group
Group type: COMPARATOR
Intervention: IRE alone (Group B)
Number of subjects: 62
Study 33297719 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulipristal Acetate (UPA) 5 mg/day
Number of subjects: 95
Study 33297719 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 35222686 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasonography (EUS)
Number of subjects: 72
Study 35222686 — intervention group
Group type: COMPARATOR
Intervention: Pathological examination
Number of subjects: 72
Study 32583431 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm A (twice weekly bortezomib in one six-week cycle followed by eight five-week cycles of four times once weekly bortezomib with melphalan and prednisolone on days 1–4)
Number of subjects: 91
Study 32583431 — intervention group
Group type: COMPARATOR
Intervention: Arm B (nine four-week cycles of three times once weekly bortezomib with melphalan and prednisolone on days 1–4)
Number of subjects: 91
Study 34146100 — intervention group
Group type: EXPERIMENTAL
Intervention: RSVPreF3 vaccine (30/60/120 µg)
Number of subjects: 502
Study 34146100 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 502
Study 34435472 — intervention group
Group type: COMPARATOR
Intervention: PP0 (0 pmol*kg‐1 *min‐1)
Number of subjects: 12
Study 34435472 — intervention group
Group type: EXPERIMENTAL
Intervention: PP3 (3 pmol*kg‐1 *min‐1)
Number of subjects: 12
Study 34435472 — intervention group
Group type: EXPERIMENTAL
Intervention: PP10 (10 pmol*kg‐1 *min‐1)
Number of subjects: 12
Study 33239409 — intervention group
Group type: EXPERIMENTAL
Intervention: Esaxerenone (1.25 mg/d titrated to 2.5 mg/d)
Number of subjects: 455
Study 33239409 — intervention group
Group type: EXPERIMENTAL
Intervention: Esaxerenone
Number of subjects: 455
Study 33239409 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 455
Study 36075311 — intervention group
Group type: EXPERIMENTAL
Intervention: Socially-oriented negative affect induction
Number of subjects: 116
Study 36075311 — intervention group
Group type: COMPARATOR
Intervention: Neutral affect induction
Number of subjects: 116
Study 36075311 — intervention group
Group type: EXPERIMENTAL
Intervention: All participants (regardless of condition)
Number of subjects: 116
Study 36075311 — intervention group
Group type: EXPERIMENTAL
Intervention: High sugar beverage consumption
Number of subjects: 116
Study 36322536 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoor environment
Number of subjects: 48
Study 36322536 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated outdoor environment
Number of subjects: 48
Study 36322536 — intervention group
Group type: EXPERIMENTAL
Intervention: Outdoor environment
Number of subjects: 48
Study 34371803 — intervention group
Group type: EXPERIMENTAL
Intervention: 10,000 IU/day for 8 weeks followed by 1000 IU/day for 4 weeks
Number of subjects: 75
Study 34371803 — intervention group
Group type: EXPERIMENTAL
Intervention: 50,000 IU/week for 12 weeks
Number of subjects: 75
Study 34371803 — intervention group
Group type: EXPERIMENTAL
Intervention: 100,000 IU every other week for 12 weeks
Number of subjects: 75
Study 34371803 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 75
Study 32521250 — intervention group
Group type: EXPERIMENTAL
Intervention: TS-121 10 mg
Number of subjects: 51
Study 32521250 — intervention group
Group type: EXPERIMENTAL
Intervention: TS-121 50 mg
Number of subjects: 51
Study 32521250 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 35708559 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure
Number of subjects: 0
Study 35708559 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 32014520 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 200 mg followed by misoprostol 800 mcg buccally
Number of subjects: 719
Study 33203692 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab plus 5-fluorouracil and oxaliplatin
Number of subjects: 1209
Study 33203692 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic variants in the retinoic acid receptor alpha (RARA) gene
Number of subjects: 1209
Study 32086878 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF/FTC
Number of subjects: 389
Study 32086878 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 389
Study 33687734 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongue cleaning with routine oral care
Number of subjects: 24
Study 33687734 — intervention group
Group type: COMPARATOR
Intervention: Routine oral care alone (Control)
Number of subjects: 24
Study 33118727 — intervention group
Group type: EXPERIMENTAL
Intervention: Bretschneider's HTK solution
Number of subjects: 50
Study 33118727 — intervention group
Group type: COMPARATOR
Intervention: Cold blood cardioplegia
Number of subjects: 50
Study 36148735 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-thumbs encircling hand technique (TTHT)
Number of subjects: 33
Study 36148735 — intervention group
Group type: COMPARATOR
Intervention: Two-fingers technique (TFT)
Number of subjects: 33
Study 32527261 — intervention group
Group type: EXPERIMENTAL
Intervention: PopART standard of care door‐to‐door HTS plus oral HIVST (33 clusters)
Number of subjects: 66
Study 32527261 — intervention group
Group type: COMPARATOR
Intervention: PopART standard of care door‐to‐door HTS (33 clusters)
Number of subjects: 66
Study 36764948 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass ionomer cement (GIC)
Number of subjects: 120
Study 36764948 — intervention group
Group type: COMPARATOR
Intervention: Compomer
Number of subjects: 120
Study 33215948 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirror Effect Plus Protocol (MEPP)
Number of subjects: 20
Study 33215948 — intervention group
Group type: COMPARATOR
Intervention: Standard medication for acute BP
Number of subjects: 20
Study 33768697 — intervention group
Group type: EXPERIMENTAL
Intervention: Omental roll-up
Number of subjects: 68
Study 33768697 — intervention group
Group type: COMPARATOR
Intervention: Non-omental roll-up
Number of subjects: 68
Study 33523087 — intervention group
Group type: EXPERIMENTAL
Intervention: Atraumatic anesthesia without a needle (Comfort‐in®)
Number of subjects: 14
Study 33523087 — intervention group
Group type: COMPARATOR
Intervention: Conventional anesthesia by blocking the posterior superior alveolar nerve (PSAN) and Greater Palatine Nerve (GPN)
Number of subjects: 14
Study 34231852 — intervention group
Group type: EXPERIMENTAL
Intervention: POCER index based on ulcer depth and circumference at the anastomosis at 6 months
Number of subjects: 85
Study 34231852 — intervention group
Group type: EXPERIMENTAL
Intervention: POCER index at 6 months
Number of subjects: 85
Study 34231852 — intervention group
Group type: EXPERIMENTAL
Intervention: Rutgeerts score at 6 months
Number of subjects: 85
Study 34231852 — intervention group
Group type: EXPERIMENTAL
Intervention: POCER index of ≥2
Number of subjects: 85
Study 34231852 — intervention group
Group type: EXPERIMENTAL
Intervention: Rutgeerts score of ≥i2
Number of subjects: 85
Study 34231852 — intervention group
Group type: EXPERIMENTAL
Intervention: POCER index
Number of subjects: 85
Study 34231852 — intervention group
Group type: EXPERIMENTAL
Intervention: Spearman's correlation of POCER index with Rutgeerts score
Number of subjects: 85
Study 34190882 — intervention group
Group type: EXPERIMENTAL
Intervention: FOCUS-PDCA procedure
Number of subjects: 160
Study 34190882 — intervention group
Group type: COMPARATOR
Intervention: Routine nursing intervention (Control)
Number of subjects: 160
Study 33662594 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed outreach strategy to promote HCC surveillance
Number of subjects: 1200
Study 33662594 — intervention group
Group type: EXPERIMENTAL
Intervention: Regularized logistic regression (RLR) model
Number of subjects: 1200
Study 33662594 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradient boosting machine (GBM) model
Number of subjects: 1200
Study 33662594 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive models
Number of subjects: 1200
Study 33509056 — intervention group
Group type: EXPERIMENTAL
Intervention: Breath awareness training
Number of subjects: 162
Study 33509056 — intervention group
Group type: EXPERIMENTAL
Intervention: Loving-kindness training
Number of subjects: 162
Study 33509056 — intervention group
Group type: EXPERIMENTAL
Intervention: Gratitude training
Number of subjects: 162
Study 33509056 — intervention group
Group type: COMPARATOR
Intervention: Attentional control
Number of subjects: 162
Study 34212120 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative focus groups and interviews with parents, former patients, and clinicians
Number of subjects: 0
Study 34212120 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial design incorporating parent and former patient perspectives
Number of subjects: 0
Study 34212120 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-sided leaflet providing information
Number of subjects: 0
Study 34212120 — intervention group
Group type: EXPERIMENTAL
Intervention: Addressing clinician biases
Number of subjects: 0
Study 33127947 — intervention group
Group type: EXPERIMENTAL
Intervention: L. reuteri oil drops and ω‐3 PUFA capsules
Number of subjects: 88
Study 33127947 — intervention group
Group type: EXPERIMENTAL
Intervention: ω‐3 PUFA supplementation
Number of subjects: 88
Study 33127947 — intervention group
Group type: EXPERIMENTAL
Intervention: L. reuteri and placebo regarding ω‐3 PUFA
Number of subjects: 88
Study 33127947 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules and placebo oil drops
Number of subjects: 88
Study 616805373 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractic spinal manipulative therapy
Number of subjects: 0
Study 616805373 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33714862 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment (OMT)
Number of subjects: 116
Study 32268971 — intervention group
Group type: EXPERIMENTAL
Intervention: CACFP sites
Number of subjects: 680
Study 32268971 — intervention group
Group type: COMPARATOR
Intervention: Non-CACFP sites
Number of subjects: 680
Study 34455801 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical inoculation with peanut leaf sap containing TuMV; confirmed by RT-PCR and western blot assay.
Number of subjects: 6
Study 34455801 — intervention group
Group type: COMPARATOR
Intervention: Mock-inoculated plants (control group).
Number of subjects: 6
Study 32451010 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupressure (AA) applied for six days per trial, total of 2 trials
Number of subjects: 42
Study 32451010 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 42
Study 36475283 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel information booklet
Number of subjects: 64
Study 36475283 — intervention group
Group type: COMPARATOR
Intervention: Currently available written OA resource
Number of subjects: 64
Study 34438047 — intervention group
Group type: COMPARATOR
Intervention: Heart-rate variability biofeedback (BFB)
Number of subjects: 80
Study 34438047 — intervention group
Group type: COMPARATOR
Intervention: Combined treatment (BFB + TDCS)
Number of subjects: 80
Study 34438047 — intervention group
Group type: COMPARATOR
Intervention: Left dlPFC anodal tDCS (TDCS)
Number of subjects: 80
Study 34438047 — intervention group
Group type: COMPARATOR
Intervention: Neutral video viewing (CTRL)
Number of subjects: 80
Study 35429046 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert-match treatment
Number of subjects: 402
Study 35429046 — intervention group
Group type: COMPARATOR
Intervention: Self-matching treatment
Number of subjects: 402
Study 35429046 — intervention group
Group type: EXPERIMENTAL
Intervention: High neuroticism score
Number of subjects: 402
Study 35429046 — intervention group
Group type: EXPERIMENTAL
Intervention: High neuroticism, openness, extraversion; low conscientiousness
Number of subjects: 402
Study 35429046 — intervention group
Group type: EXPERIMENTAL
Intervention: Low conscientiousness
Number of subjects: 402
Study 32730977 — intervention group
Group type: EXPERIMENTAL
Intervention: Bumetanide (1.0 mg twice daily for 91 days)
Number of subjects: 92
Study 32730977 — intervention group
Group type: EXPERIMENTAL
Intervention: Bumetanide
Number of subjects: 92
Study 32236116 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-meal walking for 15-20 minutes after one meal a day for 6 weeks
Number of subjects: 14
Study 32236116 — intervention group
Group type: COMPARATOR
Intervention: One prandial insulin injection before breakfast or main meal with rapid-acting insulin
Number of subjects: 14
Study 32236116 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-meal walking
Number of subjects: 14
Study 32236116 — intervention group
Group type: COMPARATOR
Intervention: One prandial insulin injection
Number of subjects: 14
Study 616121059 — intervention group
Group type: EXPERIMENTAL
Intervention: Drop A (propylene glycol and glycerin containing drop)
Number of subjects: 15
Study 616121059 — intervention group
Group type: EXPERIMENTAL
Intervention: Drop B (carbomer containing drop)
Number of subjects: 15
Study 616121059 — intervention group
Group type: COMPARATOR
Intervention: Saline eye drop (Ocufresh eye wash)
Number of subjects: 15
Study 36027558 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan (SG)
Number of subjects: 543
Study 36027558 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (eribulin, vinorelbine, capecitabine, or gemcitabine)
Number of subjects: 543
Study 36027558 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 543
Study 33951360 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifapentine with moxifloxacin
Number of subjects: 2516
Study 33951360 — intervention group
Group type: COMPARATOR
Intervention: Control (6-month regimen with rifampin, isoniazid, pyrazinamide, and ethambutol)
Number of subjects: 2516
Study 33951360 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifapentine without moxifloxacin
Number of subjects: 2516
Study 35299013 — intervention group
Group type: EXPERIMENTAL
Intervention: 360-degree VR-video
Number of subjects: 83
Study 35299013 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard information leaflet)
Number of subjects: 83
Study 33373445 — intervention group
Group type: EXPERIMENTAL
Intervention: Diacutaneous Fibrolysis (DF)
Number of subjects: 39
Study 34024658 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV10 (n=55)
Number of subjects: 101
Study 34024658 — intervention group
Group type: COMPARATOR
Intervention: PCV13 (n=46)
Number of subjects: 101
Study 34024658 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV10
Number of subjects: 101
Study 34024658 — intervention group
Group type: COMPARATOR
Intervention: PCV13
Number of subjects: 101
Study 36494726 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperspectral imaging (HSI) group
Number of subjects: 51
Study 36494726 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 51
Study 34831691 — intervention group
Group type: EXPERIMENTAL
Intervention: Almond protein powder
Number of subjects: 20
Study 34831691 — intervention group
Group type: COMPARATOR
Intervention: Whey protein powder
Number of subjects: 20
Study 36127557 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic Gastrectomy (RG)
Number of subjects: 65
Study 36127557 — intervention group
Group type: COMPARATOR
Intervention: Open Gastrectomy (OG)
Number of subjects: 65
Study 32250463 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg twice daily (Day 8) and once daily (Days 9–16) with a single oral 2.5 mg dose of esaxerenone
Number of subjects: 32
Study 32250463 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin 600 mg once daily (Days 8–16) with a single oral 5 mg dose of esaxerenone
Number of subjects: 32
Study 33378776 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral colostomy (LC)
Number of subjects: 203
Study 33378776 — intervention group
Group type: COMPARATOR
Intervention: Conventional colostomy (CC)
Number of subjects: 203
Study 33337397 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized Balance Training + Conventional Physiotherapy (40 minutes once a day, 5 times a week for 4 weeks)
Number of subjects: 32
Study 33337397 — intervention group
Group type: COMPARATOR
Intervention: Conventional Physiotherapy (40 minutes twice a day, 5 times a week for 4 weeks)
Number of subjects: 32
Study 35368096 — intervention group
Group type: EXPERIMENTAL
Intervention: PAC quality improvement interventions emphasizing family planning counseling and voluntary access to LARC in mainland Tanzania.
Number of subjects: 0
Study 35368096 — intervention group
Group type: EXPERIMENTAL
Intervention: PAC quality improvement interventions emphasizing family planning counseling and voluntary access to LARC in Zanzibar.
Number of subjects: 0
Study 35368096 — intervention group
Group type: EXPERIMENTAL
Intervention: PAC quality improvement interventions in Zanzibar.
Number of subjects: 0
Study 33616561 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-implant mandibular overdentures (IODs)
Number of subjects: 29
Study 33616561 — intervention group
Group type: COMPARATOR
Intervention: Conventional mandibular dentures relined (RCD)
Number of subjects: 29